Pure Financial Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $601K | Sell |
24,963
-4,953
| -17% | -$130K | 0.01% | 336 |
|
|
2026
Q1 | $840K | Sell |
29,916
-734
| -2% | -$19.5K | 0.01% | 241 |
|
|
2025
Q4 | $763K | Sell |
30,650
-58
| -0.2% | -$1.46K | 0.01% | 251 |
|
|
2025
Q3 | $782K | Sell |
30,708
-2,333
| -7% | -$57.6K | 0.01% | 241 |
|
|
2025
Q2 | $801K | Buy |
33,041
+9,183
| +38% | +$214K | 0.01% | 228 |
|
|
2025
Q1 | $605K | Sell |
23,858
-1,108
| -4% | -$29K | 0.01% | 220 |
|
|
2024
Q4 | $662K | Buy |
24,966
+2,945
| +13% | +$79.9K | 0.02% | 190 |
|
|
2024
Q3 | $637K | Sell |
22,021
-5,680
| -21% | -$166K | 0.02% | 192 |
|
|
2024
Q2 | $775K | Sell |
27,701
-894
| -3% | -$24.6K | 0.02% | 163 |
|
|
2024
Q1 | $794K | Buy |
28,595
+5,738
| +25% | +$159K | 0.02% | 159 |
|
|
2023
Q4 | $658K | Buy |
22,857
+625
| +3% | +$18.9K | 0.02% | 169 |
|
|
2023
Q3 | $737K | Buy |
22,232
+1,495
| +7% | +$52.9K | 0.03% | 143 |
|
|
2023
Q2 | $761K | Sell |
20,737
-5,850
| -22% | -$228K | 0.03% | 139 |
|
|
2023
Q1 | $1.08M | Buy |
26,587
+1,341
| +5% | +$57.9K | 0.05% | 122 |
|
|
2022
Q4 | $1.29M | Sell |
25,246
-39
| -0.2% | -$1.87K | 0.07% | 106 |
|
|
2022
Q3 | $1.11M | Buy |
25,285
+2,181
| +9% | +$106K | 0.06% | 108 |
|
|
2022
Q2 | $1.21M | Sell |
23,104
-4,364
| -16% | -$222K | 0.08% | 106 |
|
|
2022
Q1 | $1.42M | Buy |
27,468
+956
| +4% | +$49.6K | 0.07% | 95 |
|
|
2021
Q4 | $1.57M | Buy |
26,512
+655
| +3% | +$32.5K | 0.08% | 85 |
|
|
2021
Q3 | $1.11M | Buy |
25,857
+805
| +3% | +$35.7K | 0.09% | 90 |
|
|
2021
Q2 | $981K | Buy |
25,052
+12
| +0% | +$467 | 0.08% | 93 |
|
|
2021
Q1 | $907K | Buy |
25,040
+640
| +3% | +$22.7K | 0.09% | 93 |
|
|
2020
Q4 | $898K | Sell |
24,400
-1,165
| -5% | -$42.7K | 0.11% | 88 |
|
|
2020
Q3 | $890K | Buy |
25,565
+107
| +0.4% | +$3.75K | 0.13% | 79 |
|
|
2020
Q2 | $790K | Buy |
25,458
+421
| +2% | +$14.3K | 0.12% | 77 |
|
|
2020
Q1 | $775K | Sell |
25,037
-1,536
| -6% | -$52.3K | 0.13% | 72 |
|
|
2019
Q4 | $988K | Buy |
26,573
+803
| +3% | +$28.6K | 0.17% | 68 |
|
|
2019
Q3 | $878K | Sell |
25,770
-5,546
| -18% | -$202K | 0.16% | 72 |
|
|
2019
Q2 | $1.29M | Buy |
31,316
+73
| +0.2% | +$2.9K | 0.23% | 57 |
|
|
2019
Q1 | $1.26M | Sell |
31,243
-765
| -2% | -$30.6K | 0.24% | 56 |
|
|
2018
Q4 | $1.33M | Buy |
32,008
+809
| +3% | +$33.6K | 0.27% | 51 |
|
|
2018
Q3 | $1.3M | Buy |
+31,199
| New | +$1.2M | 0.29% | 51 |
|
|
2017
Q4 | – | Sell |
-24,267
| Closed | -$822K | – | 69 |
|
|
2017
Q3 | $822K | Buy |
24,267
+524
| +2% | +$16.8K | 0.21% | 48 |
|
|
2017
Q2 | $757K | Buy |
23,743
+459
| +2% | +$14.5K | 0.2% | 49 |
|
|
2017
Q1 | $756K | Buy |
23,284
+89
| +0.4% | +$2.81K | 0.22% | 49 |
|
|
2016
Q4 | $715K | Buy |
23,195
+219
| +1% | +$6.69K | 0.21% | 49 |
|
|
2016
Q3 | $738K | Buy |
22,976
+4,456
| +24% | +$149K | 0.24% | 43 |
|
|
2016
Q2 | $619K | Buy |
18,520
+220
| +1% | +$7.02K | 0.21% | 45 |
|
|
2016
Q1 | $522K | Sell |
18,300
-329
| -2% | -$9.4K | 0.19% | 50 |
|
|
2015
Q4 | $571K | Hold |
18,629
| – | – | 0.25% | 36 |
|
|
2015
Q3 | $555K | Sell |
18,629
-3,161
| -15% | -$101K | 0.26% | 31 |
|
|
2015
Q2 | $693K | Buy |
21,790
+10,865
| +99% | +$354K | 0.34% | 29 |
|
|
2015
Q1 | $361K | Sell |
10,925
-1,745
| -14% | -$55.5K | 0.12% | 43 |
|
|
2014
Q4 | $374K | Buy |
12,670
+1,257
| +11% | +$36K | 0.13% | 46 |
|
|
2014
Q3 | $320K | Sell |
11,413
-1,648
| -13% | -$46.3K | 0.12% | 43 |
|
|
2014
Q2 | $368K | Buy |
+13,061
| New | +$372K | 0.14% | 44 |
|
Other funds holding PFE
Pure Financial Advisors's PFE Position: Q2 2026 in Review
Pure Financial Advisors reduced its Pfizer (PFE) stake by 17% in Q2 2026, selling an estimated $130K and leaving 24,963 shares worth $601K. The position accounts for 0.01% of the portfolio, ranked #336.
Pure Financial Advisors first reported a position in PFE in Q2 2014 and has held it in 46 quarters since. The position peaked at $1.57M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Pure Financial Advisors held 24,963 shares of Pfizer worth $601K as of Q2 2026.
- Pure Financial Advisors sold 4,953 Pfizer shares in Q2 2026, an estimated $130K.
- Pfizer made up 0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #336 holding.
- Pure Financial Advisors first reported a position in Pfizer in Q2 2014 and has held it in 46 quarters since.
- Pure Financial Advisors's Pfizer position peaked at $1.57M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.